Quality control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group

被引:19
|
作者
Favalli, G
Vermorken, JB
Vantongelen, K
Renard, J
Van Oosterom, AT
Pecorelli, S
机构
[1] Univ Antwerp Hosp, Dept Med Oncol, B-2650 Edegem, Belgium
[2] Univ Brescia, Spedali Civili, Dept Gynecol Oncol, Brescia, Italy
[3] Univ Hosp Gasthuisberg, Dept Oncol, B-3000 Louvain, Belgium
[4] Eortc Data Ctr, Brussels, Belgium
关键词
quality control; multicentric trials; chemotherapy;
D O I
10.1016/S0959-8049(00)00090-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data Quality is a central requirement of scientific research and external monitoring is essential in multicentric clinical trials (MCT). A quality control (QC) study was conducted in the main Institutions participating in EORTC-GCCG Protocol number 55863 - randomised phase III trial of vindesine. cisplatin, bleomycin and mitomycin-C (BEMP) versus cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix - in order to assess the impact of variations in data quality on the conclusions of the trial. The reliability of the different centres in following the protocol was investigated by a questionnaire covering drug prescription, local facilities and the procedure for preparation and administration of chemotherapy. The 'treatment protocol adherence' was evaluated by recalculation of the ideal protocol dose and its comparison with the actual delivered dosage at each cycle of chemotherapy. 'Data quality control' was assessed by comparison of data on case report forms (CRFs) with the corresponding items in the medical records. Eleven centres participating in the trial were visited by the same team of reviewers. Striking differences were noted in the chemotherapy administration procedures and between the type and quality of hospital files. Overall. there was an acceptable level of data quality and protocol compliance. Data accuracy was 81.8% (range: 65.6-97%) of the 4424 items checked. Incorrect data were found in 7.0% (2.3-14.5%), data were missing on the form in 3.6% of cases (0-12%) and data was on the form but not in the file in 7.6% of cases (0.7-17.5%). Causes of inaccuracy were analysed. Both problems in data management but also in a lack of clarity of the protocol and/or CRFs were to blame. Training and supervision of data managers, precision in writing protocols, standardisation of some aspects of CRFs and the use of a checklist for chemotherapy data and treatment toxicities would have avoided many of these errors. The need for QC in all collaborative groups performing MCT is emphasised. A literature review on QC in MCT dealing with chemotherapy is included. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1125 / 1133
页数:9
相关论文
共 50 条
  • [1] The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC soft tissue and bone sarcoma group
    Verweij, J
    Nielsen, OS
    Therasse, P
    vanOosterom, AT
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) : 1045 - 1049
  • [2] CLINICAL COOPERATIVE TRIALS OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA CLINICAL-TRIALS-GROUP BREAST-CANCER-SITE-GROUP
    PRITCHARD, KI
    CANCER, 1994, 74 (03) : 1150 - 1155
  • [3] Participation of elderly gynecological cancer patients in clinical trials
    Prieske, Katharina
    Trillsch, Fabian
    Oskay-Ozcelik, Gulten
    Chekerov, Radoslav
    Bleich, Christiane
    Oliveira-Ferrer, Leticia
    Grimm, Donata
    Kuerti, Sascha
    Mueller, Volkmar
    Suling, Anna
    Schmalfeldt, Barbara
    Sehouli, Jalid
    Mahner, Sven
    Woelber, Linn
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2018, 298 (04) : 797 - 804
  • [4] Participation of elderly gynecological cancer patients in clinical trials
    Katharina Prieske
    Fabian Trillsch
    Gülten Oskay-Özcelik
    Radoslav Chekerov
    Christiane Bleich
    Leticia Oliveira-Ferrer
    Donata Grimm
    Sascha Kuerti
    Volkmar Mueller
    Anna Suling
    Barbara Schmalfeldt
    Jalid Sehouli
    Sven Mahner
    Linn Woelber
    Archives of Gynecology and Obstetrics, 2018, 298 : 797 - 804
  • [5] 5-AZA-2'-DEOXYCYTIDINE (NSC-127716) IN NONSEMINOMATOUS TESTICULAR CANCER - PHASE-II FROM THE EORTC EARLY CLINICAL-TRIALS COOPERATIVE GROUP AND GENITOURINARY GROUP
    CLAVEL, M
    MONFARDINI, S
    FOSSA, S
    SMYTH, J
    RENARD, J
    KAYE, SB
    DROZD, A
    DODION, P
    SPLINTER, TAW
    STOTER, G
    HUININK, WWT
    ANNALS OF ONCOLOGY, 1992, 3 (05) : 399 - 400
  • [6] Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
    Aapro, MS
    van Wijk, FH
    van der Burg, MEL
    Huinink, WT
    Vergote, I
    Guastalla, JP
    Rosso, R
    Kobierska, A
    Beex, LVA
    Namer, M
    Splinter, TEW
    Vermorken, JB
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (08) : 1141 - 1143
  • [7] Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer
    Joly, F.
    Vardy, J.
    Pintilie, M.
    Tannock, I. F.
    ANNALS OF ONCOLOGY, 2007, 18 (12) : 1935 - 1942
  • [8] Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group
    Dreicer, R
    Roth, B
    Wilding, G
    CANCER, 2003, 97 (08) : 2109 - 2114
  • [9] Pancreas cancer trials for early stage disease: Surgeons leading therapeutic cooperative group trials
    Snyder, Rebecca A.
    Ahmad, Syed
    Katz, Matthew H. G.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 125 (01) : 75 - 83
  • [10] Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma - An EORTC Gynecological Cancer Group Study
    Wagenaar, HC
    Pecorelli, S
    Vergote, I
    Curran, D
    Wagener, DJT
    Kobierska, A
    Bolis, G
    ten Bokkel-Huinink, W
    Lacave, AJ
    Madronal, C
    Forni, M
    de Oliveira, CF
    Mangioni, C
    Nooij, MA
    Goupil, A
    Kerbrat, P
    Marth, C
    Tumolo, S
    Herben, MG
    Zanaboni, F
    Vermorken, JB
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2001, 22 (03) : 187 - 193